Literature DB >> 9098583

Troglitazone inhibits type 2KATP channel activity and depolarises tolbutamide-sensitive neurones in the rat ventromedial hypothalamus.

K Lee1, P Boden.   

Abstract

Patch-clamp recording techniques were used to examine the effect of troglitazone upon visually identified neurones contained in slices from the rat ventromedial hypothalamus. Bath application of 1-50 microM troglitazone depolarised tolbutamide-sensitive neurones in a poorly reversible manner. In outside-out patches, troglitazone inhibited KATP channel activity when added to the bath solution. It is concluded that troglitazone is a novel modulator of the type 2 KATP channel.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9098583     DOI: 10.1016/s0006-8993(97)00046-2

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  4 in total

Review 1.  PPAR-γ as a therapeutic target in cardiovascular disease: evidence and uncertainty.

Authors:  Janice V Huang; Clifford R Greyson; Gregory G Schwartz
Journal:  J Lipid Res       Date:  2012-06-08       Impact factor: 5.922

2.  Thiazolidinedione drugs promote onset, alter characteristics, and increase mortality of ischemic ventricular fibrillation in pigs.

Authors:  Mohammad Sarraf; Li Lu; Shuyu Ye; Michael J Reiter; Clifford R Greyson; Gregory G Schwartz
Journal:  Cardiovasc Drugs Ther       Date:  2012-06       Impact factor: 3.727

3.  Deleterious effects of acute treatment with a peroxisome proliferator-activated receptor-gamma activator in myocardial ischemia and reperfusion in pigs.

Authors:  Ya Xu; Li Lu; Clifford Greyson; Jenny Lee; Michael Gen; Koichiro Kinugawa; Carlin S Long; Gregory G Schwartz
Journal:  Diabetes       Date:  2003-05       Impact factor: 9.461

4.  Thiazolidinedione drugs block cardiac KATP channels and may increase propensity for ischaemic ventricular fibrillation in pigs.

Authors:  L Lu; M J Reiter; Y Xu; A Chicco; C R Greyson; G G Schwartz
Journal:  Diabetologia       Date:  2008-02-05       Impact factor: 10.122

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.